Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Acute Schizophrenic Psychosis
NCT00309413Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Mar 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in schizophrenia and schizophreniform disorder (2 arms), sponsored by University of Cologne. Primary endpoint: Brief Psychiatric Rating Scale at 4 weeks. Started Mar 2006; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniaschizophreniform disorder
Beyond the preview
Go deeper on NCT00309413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309413.